An interventional study of Choosing to receive the vaccine in Herpes Zoster, sponsored by NYU Langone Health. Completed at 2 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-09.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Health services research
The purpose of this study is to determine if vaccination rate of eligible patients at a major urban public hospital will increase by having ophthalmologists screen patients for eligibility and a nurse administer the vaccine in the General Eye Clinic.
Patient vaccination behaviors will be assessed after 100 doses of the Zostavax vaccine are provided to underserved patients screened by ophthalmologists at the General Eye Clinic at a public hospital that does not normally provide the vaccine. A nurse will be at the clinic to administer the vaccine. Patients will be contacted by phone 1 month later and seen within 3 months in the Eye Clinic to determine whether there were any side effects.
305 studies on the registry are indexed under Herpes Simplex; 31 are open to participants now.
This study's enrollment of 170 is above the median of 101 across 227 interventional studies indexed under Herpes Simplex.
Browse Herpes Simplex studies →NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.
Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
Other: Choosing to receive the vaccine
Answers to Survey Questions
All enrolled patients completed a survey of baseline characteristics, eligibility for the herpes zoster vaccine, and attitudes regarding herpes zoster vaccination. The survey results from patients who agreed to receive the herpes zoster vaccine were compared to the results of patients who declined to be vaccinated.
Time frame: January 9, 2012 to February 12, 2012
We prospectively recruited eligible patients from the Bellevue Eye clinic until 100 patients were prescribed and received the vaccine. Recruitment occurred from January 9, 2012 to February 12, 2012.
| Milestone | Patients Who Received the Herpes Zoster Vaccine | Patients Who Declined the Herpes Zoster Vaccine |
|---|---|---|
| Started | 100 | 66 |
| Completed | 100 | 66 |
| Not completed | 0 | 0 |
All enrolled patients completed a survey of baseline characteristics, eligibility for the herpes zoster vaccine, and attitudes regarding herpes zoster vaccination. The survey results from patients who agreed to receive the herpes zoster vaccine were compared to the results of patients who declined to be vaccinated.
| Percentage of responders | Patients Who Received the Herpes Zoster Vaccine | Patients Who Declined the Herpes Zoster Vaccine |
|---|---|---|
| Subject reported receiving flu Vaccine last year | 89 (83 to 95) | 71.2 (60 to 82) |
| Reported would receive the vaccine if recommended | 98 (95 to 100) | 74 (64 to 85) |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subjects Who Received the Herpes Zoster Vaccine | — | 0/100 (0%) | 11/100 (11%) |
| Subjects Who Declined the Herpes Zoster Vaccine | — | — | — |
| Event | Subjects Who Received the Herpes Zoster Vaccine | Subjects Who Declined the Herpes Zoster Vaccine |
|---|---|---|
| Injection Site ReactionSkin and subcutaneous tissue disorders | 11/100 | — |
170 patients were enrolled in the study, however 2 met FDA contraindications for herpes zoster vaccination and 2 already received the vaccine, so only 166 were included in the analysis.
| Age Continuous(years) | Survey Participants |
|---|---|
| Age | 68 ± 15 |
| Sex: Female, Male(Participants) | Survey Participants |
|---|---|
| Female | 94 |
| Male | 72 |
| Region of Enrollment(participants) | Survey Participants |
|---|---|
| United States | 166 |
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NYU Langone Health